Apogee Therapeutics, Inc. (APGE)
$
37.36
-2.36 (-6.32%)
Key metrics
Financial statements
Free cash flow per share
-3.1222
Market cap
2.3 Billion
Price to sales ratio
0
Debt to equity
0.0116
Current ratio
18.5474
Income quality
0.9398
Average inventory
0
ROE
-0.2187
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company focused on developing biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The financial data pertains to the fiscal year 2024. The income before tax ratio is 0.00 reflecting the pre-tax margin. The company incurred an income tax expense of -$18,000.00 indicating its tax obligations. Furthermore, the company earned an interest income of $0.00 showcasing its financial investments. The earnings per share (EPS) is reported at $0.00 indicating the company's profitability on a per-share basis. Apogee primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD, along with APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD and APG222, which consists of extended half-life SQ antibodies for AD. Founded in 2022, the company is based in Waltham, Massachusetts. The stock is affordable at $37.40 suitable for budget-conscious investors. Despite this affordability, the stock has a low average trading volume of 632,933.00 indicating lower market activity. With a mid-range market capitalization of $2,223,039,104.00 the company is a steady performer. As a key player in the Biotechnology industry, Apogee Therapeutics contributes significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company's commitment to addressing critical health issues through advanced therapeutics makes it a noteworthy entity within the biotechnology field.
What is Apogee Therapeutics, Inc. (APGE)'s stock forecast?
Analysts predict Apogee Therapeutics, Inc. stock to fluctuate between $29.10 (low) and $66.80 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Apogee Therapeutics, Inc.'s market capitalization?
As of 2025-04-01, Apogee Therapeutics, Inc.'s market cap is $2,223,039,104, based on 59,503,188 outstanding shares.
How does Apogee Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Apogee Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Apogee Therapeutics, Inc. (APGE) stock?
To buy Apogee Therapeutics, Inc. (APGE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for APGE. Place an order (Market, Limit, etc.).
What is the best time to invest in Apogee Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Apogee Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: $0 | Growth: -100%.
Where can I find Apogee Therapeutics, Inc.'s investor relations reports?
Visit https://www.apogeetherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Apogee Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Apogee Therapeutics, Inc. stock?
All-time high: $72.29 (2024-03-13) | All-time low: $14.19 (2023-11-10).
What are the key trends affecting Apogee Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025
globenewswire.com
SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE) today announced that members of management will participate at the following investor conferences.
globenewswire.com
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe AD, as well as enrollment completion in the Part A portion of the trial. “Enrollment for the Phase 2 Part A trial of APG777 surpassed the approximately 110 patient target ahead of schedule, driven by strong patient and investigator enthusiasm, underscoring the potential of APG777 to address the need for safe, effective treatment options that reduce injection burden and provide better disease control for patients with AD and other I&I conditions,” said Carl Dambkowski, M.D.
globenewswire.com
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
globenewswire.com
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
globenewswire.com
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET.
globenewswire.com
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
seekingalpha.com
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG777, justify its current valuation premium.
globenewswire.com
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences.
See all news
